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Introduction

Asherman’s syndrome (AS) is a uterine disorder characterized by intrauterine
adhesions. These adhesions, also known as synechiae, result from loss of the
regenerative cell population residing in the basalis layer of the endometrium1. Under
normal physiologic conditions, these cells clonally expand to replace the functionalis
layer of the uterus after menses or parturition2. Without a properly functioning basalis
layer, the highly vascular functionalis layer of the uterus is replaced by dense fibrotic
tissue which spans the spans the endometrial walls, and in severe cases, can completely
obliterate the uterine cavity.
In Asherman’s Syndrome, the presence of these intrauterine adhesions precludes
normal functioning of the endometrial lining. A healthy functionalis layer is required
for implantation and regular menstruation, which may be hindered or halted altogether
in AS. The lack of a functioning endometrial lining often leads to symptoms of
hypomenorrhea or amenorrhea. Implantation may be impaired as fewer viable sites are
available on the endometrial surface. Adhesions may also block the movement of either
sperm or fertilized ova to the site of fertilization or implantation, respectively.
Infertility often results; however, if pregnancy is achieved in females with AS, there is
an increased risk of abnormal placentation and pregnancy loss as the fibrous synechiae
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impair normal gestational development3. In addition to infertility, the consequences of
AS include recurrent pregnancy loss, and in pregnant women, an increased risk of
preterm premature rupture of membranes, placental abruption, and fetal
malpresentation.
There are multiple etiologies for AS. Asherman’s Syndrome occurs most
commonly after uterine instrumentation. Dilation and curettage is the most frequently
implicated procedure as vigorous scraping can lead to removal or damage of the deeper
basal layer of the endometrium, where stem cells reside. Women are at particularly
high risk in the post-partum period when the endometrium is relatively thin and
estrogen levels are low. Indeed, curettage for retained products of conception and postpartum hemorrhage are frequent mechanisms for the development of AS3. Other
etiologies of AS include severe infection of the endometrium, particularly by
Mycobacterium tuberculosis, and radiation exposure in the setting of oncologic
treatment4.
Precursors of this disease are not uncommon. One study found the presence of
intrauterine adhesions in 10% of women after one episode of curettage, and in 30% of
women with two or more curettage events. It has been estimated that 4.6% of infertile
females are affected by AS3.
Several different modalities may be used for the diagnosis of AS.
Hysterosalpingography can detect synechiae as filling defects when contrast is

3
introduced into the uterine cavity. This method has a high false positive rate as air
bubbles and debris may be misinterpreted as intrauterine adhesions. Another method of
diagnosis is transvaginal ultrasound. One hallmark seen on ultrasound is a thin uterine
lining, but this is a nonspecific finding. Visualization of synechiae can be enhanced
using saline to expand the uterine cavity, providing further contrast between the
echogenic adhesions and anechoic fluid. Interpretation of sonographic testing is limited
by the skill of the sonographer and the patient’s anatomy. Magnetic resonance imaging
can be useful in cases of complete obstruction of the internal cervical os by adhesions,
precluding other methods of diagnosis. The gold standard of diagnosis in AS is
hysteroscopy where adhesions can be directly visualized and, if appropriate, intervened
upon surgically5.
Hysteroscopy is often required for clinical staging of AS. Although many
systems of AS classification exist, none are universally implemented. The European
Society of Hysteroscopy released its classification of intrauterine adhesions in 1989.
This system consists of four separate grades. Grade I AS involves only thin, filmy
adhesions, with no disruption of the cornual regions. Grade II disease is defined by the
presence of a singular firm adhesion, which cannot be ruptured by the hysteroscope
alone, but does not obstruct visualization of both tubal ostia. Grade III AS involves
multiple firm adhesions, with unilateral obliteration of the tubal ostia. Grade IV is
reserved for extensive disease with coaptation of the uterine walls or blockage of both
tubal ostia6.
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A more recent system was created by Donnez and Nisolle in 1994. This system
includes three degrees of classification of intrauterine adhesions based primarily on
adhesion location. Degree I is designated for cases with only centrally located
adhesions. I(a) denotes thin filmy adhesions, in contrast to I(b) adhesions which are
myofibrous in character. Degree II intrauterine adhesions are marginal in location and
subdivided into II(a): wedge-like projections and II(b): adhesions with blockage of a
uterine horn. Degree III is noted for cases where the uterine cavity is absent on
hysterosalpingography due to either occlusion of the internal os, III(a), or extensive
coaptation throughout the lumen, III(b)6.
Limited treatment options exist for AS. Hysteroscopic adhesiolysis is the
standard for treatment and involves direct visualization and removal of synechiae using
a hysteroscope via blunt dissection, surgical scissors, or thermal energy. Some
providers supplement this intervention with post operative placement of an intra-uterine
balloon and one month of oral estrogen supplementation to help promote endometrial
healing, facilitate regeneration, and to prevent reformation of adhesions. Despite these
interventions, recurrence rates of synechiae can be as high as 41.9% in high grade
disease, necessitating second, third, or even fourth look hysteroscopic procedures.
Fertility outcomes after this procedure are remarkably poor. A systematic review in
2018 found a pregnancy rate of only 50.4% after surgical treatment of Asherman’s
Syndrome7. Often, women with recurrent AS must resort to surrogacy or adoption in
order to have a child.
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Recently, there has been increasing interest in bone marrow derived stem cells
(BMDSC) as a potential therapeutic approach to AS. Engraftment of stem cells to the
uterus has been shown incidentally in uterine biopsies of patients receiving allogenic
bone marrow transplants for leukemia8. Mouse studies have replicated this phenomenon
of uterine engraftment after bone marrow transplant and intravenous injection of bone
marrow derived stem cells9. Bone marrow-derived stem give rise to various nonhematopoietic endometrial cells including epithelial, stromal and endothelial cells,
suggesting that BMDSCs may serve as a source of progenitor cells for endometrial
regeneration.
Clinically, therapeutic injury to the endometrium has been used in an attempt to
improve implantation success in women with infertility resulting from endometrial
pathology. Indeed, it has been shown that ischemia/ reperfusion injury causes a
stimulus for homing and engraftment of BMDSCs into the uterus. This may represent
one mechanism by which therapeutic injury to the uterus improves endometrial
receptivity. Studies have also shown that administration of bone marrow after uterine
injury (Asherman’s Syndrome induction surgery) improves endometrial function and
increases the rate of successful pregnancy. Similarly introducing stem cell
chemoattractant in a mouse model of Asherman’s Syndrome improved uterine recovery
and pregnancy rates9.
BMDSC’s are used routinely in the treatment of hematologic malignancies such
as lymphomas, leukemias, and multiple myeloma where these transplanted cells replace
the patients absent or faulty bone marrow cells10. Experimental use of BMDSC’s is also

6
being explored as a means of regenerating articular cartilage in degenerative joint
disease and cardiomyocyte function post myocardial infarction11, 12. These successes
have generated further interest in exploring this treatment modality in AS13. Indeed,
improved fertility outcomes have been shown in a murine model of AS with tail vein
injection of BMDSC’s14.
In patients with AS, there is thought to be insufficient recruitment of one’s own
native stem cells. Stem cell therapy has been piloted in several studies as a means to
improve infertility and menstrual symptoms in patients with AS. Methodologies include
mobilization and peripheral collection of stem cells with the mobilizing agent
granulocyte colony stimulating factor (G-CSF). Other studies utilized stem cells
obtained directly via bone marrow aspiration. Endometrial mesenchymal stem cells
demonstrate reduced clonogenic potential in patients experiencing recurrent pregnancy
loss. This strongly suggests functional stem cell deficiency in these patients. Thus,
supplying bone marrow derived stem cells to the endometrium may serve as a means by
which to replenish stem cells in the endometrium, and effectively treat AS by allowing
for normal endometrial regeneration and replenishment of essential endometrial stem
cells.
There have been several case reports demonstrating success with stem cell use
in human subjects with AS. In 2011, a 33-year-old woman with AS underwent
successful implantation with in vitro fertilization five months after introduction of
autologous stem cells into the uterine cavity15. A case series in 2014 of six women with
severe AS looked at sub-endometrial zone injection of stem cells via ultrasound
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guidance. Five out of the six women achieved menstruation after previously being
amenorrheic16. Santamaria et. al. injected stem cells into the spiral arterioles of eleven
women with refractory AS. All eleven subjects experienced an increase in endometrial
thickness, three had spontaneous pregnancies, and three achieved pregnancy with
embryo transfer17.
These studies have used apheresis and subsequent injection as a means of
introducing stem cells into the damaged endometrium. Peripheral mobilization is
another method of harnessing BMDSC’s. This involves using pharmacologic agents to
release stem cells from the bone marrow into the systemic circulation. Once in the
serum, stem cells can home to sites of injury and exact their regenerative effects. This
method is more efficient and less invasive as it involves a single administration of a
medication and avoids the discomfort and potential complications of bone marrow
aspiration and peripheral blood draws.
Historically mobilization was achieved using G-CSF alone. However, a subset
of patients fails to mobilize BMDSCs effectively with administration of this singular
agent. Mobilization via 1,1'-[1,4-phenylenebis-(methylene)]-bis-1,4,8,11tetraazacyclotetradecane (AMD3100) was approved in 2008 by the FDA. Utilization of
AMD3100 and GCSF for mobilization of stem cells for transplantation results in
successful engraftment in nearly all patients. In one trial utilizing healthy donors, a
single dose was effective in 75% of individuals. Common side effects include erythema
or stinging at the injection site, peri-oral paresthesia, nausea, diarrhea, and headache18,
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. No significant changes in serum values of electrolytes, blood urea nitrogen,

creatinine, liver function markers, bilirubin, or alkaline phosphatase has been reported
with this agent. AMD3100’s dosing is weight based, and one subcutaneous
administration, on average, allows for mobilization of 2 x10^6 stem cells20.
AMD3100 functions by antagonizing interactions between the C-X-C Motif
Chemokine Receptor 4 (CXCR4) and the chemokine Stromal Cell-Derived Factor-1
(SDF-1), also known as C-X-C Motif Chemokine Ligand 12 (CXCL12). The CXCR4
receptor is located on BMDSC’s and binds CXCL12 via powerful disulfide bones,
which are responsible for securing the cells’ location within the bone marrow21. By
disrupting these bonds, AMD3100 allows BMDSC’s to travel through the systemic
vasculature and then enter inflamed tissues. Currently, AMD3100 is used to augment
peripheral stem cell collection in patients who are poor mobilizers.
The benefits of AMD3100 use without peripheral cell collection have been
postulated in several disease states22. In Asherman’s Syndrome specifically, this agent
could be used after hysteroscopic lysis of intrauterine adhesions to facilitate proper
healing and reduce the risk of synechiae recurrence. Yet, the ideal timing for
administration of AMD3100 for this purpose is unknown.
Recently, it has been shown that CXCL12 is one of the predominate mediators
of stem cell engraftment to the uterus after injury23. Stem cells follow a gradient of
CXCL12 released from inflamed tissues to ultimately home to sites of damage. It has
also been shown that daily administration of AMD3100 can block engraftment of stem
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cell to the uterus, by precluding the formation of interactions necessary to stabilize
residence in the uterine stroma. To optimize the restorative effects of AMD3100, its
peak mobilizing effects should coincide temporally with peak concentrations of
CXCL12 located in the target organ. Furthermore, consideration must be paid to its
half-life, allowing adequate time for this medication to be processed and excreted, thus
permitting formation of the new receptor interactions necessary for proper engraftment
at sites of injury. In contrast, if AMD3100’s antagonistic effects on the CXCR4
receptor remain throughout a target organs receptive window, recruitment may never
occur, and optimal healing may not be achieved.
AMD3100 has a half-life of twenty minutes and a terminal half-life between
three and five hours. Peak mobilization of BMDSC’s with AMD3100 occurs six to nine
hours after administration in human subjects22. Post injury CXCL12 levels have been
studied in various tissues as well. One study found a peak in CXCL12 concentration in
the cardiomyocytes of rats one hour after myocardial infarction24. Peak concentrations
in mouse kidney occurs ninety minutes after ischemia-reperfusion injury25. CXCL12
concentrations in mouse femur peaks three days after fracture26. To date, there are no
studies analyzing peak CXCL12 levels in the uterus after injury. Thus, I hypothesize
that systemic delivery of BMDSCs to the uteri of mice with surgically induced
Asherman’s Syndrome through the use of AMD3100 would have a beneficial effect on
the endometrium—subsequently restoring fertility— and is dependent on timing of
peak CXCL12 levels in the uteri.
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Statement of Purpose

1. Optimize a murine model of Asherman’s Syndrome.
2. Assess fertility outcomes in mild Asherman’s Syndrome model mice treated
with AMD3100.
3. Determine timing of peak serum and uterine levels of CXCL12 after AS
induction.
4. Identify an optimal time point for AMD3100 administration in AS.
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Materials and Methods

Student Contributions: Surgeries were taught by Dr. Flores and performed by the
author. Statistical analysis was performed under the guidance of Dr. Flores. Mouse
blood collection was performed by Ramanaiah Mamillapalli, Ph.D. Protein extraction
reagents were mixed and aliquoted by George Zhou. All other tasks were performed by
the author.
Ethics statement: This research was performed with the utmost consideration toward
academic integrity and ethical treatment of research animals.

Mice
C57BL/6 wild-type mice were purchased from Charles River Laboratories
(Wilmington, MA). Mice were housed and maintained (four to five per cage) in a room
(21 ± 1°C) with a 12-h light/dark cycle (7:00 a.m. to 7:00 p.m.) with ad libitum access
to food and water, in the Yale Animal Resources Center (YARC) at Yale School of
Medicine. All animal experiments were conducted in accordance with an approval
protocol from the Institutional Animal Care and Use Committee (IACUC) appointed by
Yale University22. All experiments were performed on mice eight to twelve weeks of
age.
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Determination of the estrus phase was essential for ensuring consistency in
endometrial susceptibility to surgical injury and assessing timed-pregnancy measures.
The estrous cycle refers to the reproductive cycle in rodents, analogous to the menstrual
cycle in humans. The estrus cycle consists of four phases, proestrus, estrus, metestrus
and diestrus. The cycle in its lasts 4 to 5 days in its entirety. The reproductive period
and estrous cycle of mice commences around day 26 of life and aligns with the opening
of the vagina. Vaginal secretions include three uniquely identifiable cell types and vary
with estrus phase. These cell types are leukocytes, cornified epithelial cells and
nucleated epithelial cells. Determination of estrus phase is most commonly based on the
proportion of these cell types in aspirates of the vaginal secretions27.
A 100µL pipette was filled with 40µL of normal saline. The pipette was placed
within the vaginal opening. The vaginal canal was washed and aspirated with the
normal saline four times sequentially. The final aspirate was dispensed on a slide and
observed under a light microscope. The diestrus phase was identified as having
numerous leukocytes and an absence of epithelial cells23. Surgeries were exclusively
performed on mice in the diestrus phase of the cycle. Mice that were found to be in
proestrus, estrus, or metestrus phase were resampled after twenty-four hours.

Asherman’s Syndrome Mouse Model- Mild
Induction of the mild variant of the murine Asherman’s Syndrome model is
based on a previously validated technique14. AS induction is only performed on mice in
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the diestrus stage of the estrus cycle. Mice were anesthetized using a mixture of
isoflurane at 2.5 L/min and oxygen at 3.0 L/min, and subsequently placed supine on a
sterile operative field. Maintenance anesthesia was provided via the same mixture
delivered by a specially designed rostral tube. A vertical incision was made in the skin
three millimeters above the vaginal margin and extended one centimeter cranially.
After careful dissection of the peritoneum from the skin and abdominal musculature, an
identical incision was made in the peritoneal membrane. The visceral fat and bladder
were mobilized allowing for identification of the left and right uterine horns. A one
centimeter, twenty-seven gauge needle was inserted into the lumen of the uterine horn
just proximal to its junction with the uterine corpus. The needle was rotated within the
lumen of the horn while simultaneously being withdrawn, causing scraping of the
needle’s bevel along the length of the endometrial surface. This procedure was repeated
four times per horn. The visceral tissues were replaced within the peritoneal cavity. The
peritoneum was sutured in a running fashion with 5.0 vicryl suture. The abdominal wall
was sutured in a running, locked fashion with 4.0 vicryl suture. Finally, the mouse was
given a unique ear tag for identification purposes then transferred to a warmed recovery
chamber.

AMD3100 Trial- Mild AS
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Mice were divided into three experimental groups: subcutaneous injection of
10mg/kg of AMD3100 eight hours before AS induction (n=7), at time of AS induction
(n=7), or seventy-two hours after AS induction (n=7). A control group received
Asherman’s Syndrome induction and subcutaneous injection of normal saline at time of
surgery (n=7).
Asherman’s Syndrome mice were stored, five to a cage, in the YARC for three
estrus cycles or twelve days after AS induction to allow for adequate recovery time
before mating. Mice were then transferred to a separate cage with a proven male,
verified to be fertile, with a ratio of three females to one male. The females were
weighed daily to assess for pregnancy. Upon reaching a weight of twenty-eight grams,
females were transferred to an individual cage and noted as pregnant. Upon delivery,
date of birth, litter size, and number of live pups was recorded. Mice that did not
achieve pregnancy within seven estrus cycles (twenty-eight days) were excluded from
the statistical analysis.

Optimization of Asherman’s Syndrome Induction Technique
I compared several different techniques for inducing Asherman’s Syndrome.
Mice were divided into one of four experimental groups: AS induction with a twentyseven gauge needle (n=4), AS induction with a twenty gauge needle (n=5), AS
induction with a twenty-seven gauge needle and micro scissor incision (n=5), and AS
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induction with a twenty gauge needle and micro scissor incision (n=5). A control group
underwent a sham surgery, in which the abdominal wall and peritoneum were incised,
the uterine horns were exposed, and the mouse was subsequently closed without direct
trauma to the uterine horns (n=4).
After twelve days of post operative recovery, mice were mated with proven
males at a ratio of three females to one male. The mice were monitored and weighed in
the fashion previously described. Litter size, live birth fraction (number of live born
pups divided by litter size), and number of miscarriages were recorded. Upon reaching
the weight of 31 grams if a mouse subsequently lost weight without delivering pups,
this was designated as a miscarriage.

Asherman’s Syndrome Mouse Model- Severe
After determining AS induction with a twenty-gauge needle and micro scissor
incision to be the preferred method for severe injury, the protocol was further modified
to be more replicable and more uniform in the trauma delivered of the uterine horns.

Mice were anesthetized, incised, and the uterine horns identified in the
previously described fashion. Using micro scissors, an incision just large enough to
accommodate the blade of the micro scissors was made immediately proximal to the
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junction of the uterine horn and uterine corpus. Then a one centimeter, twenty-gauge
needle was inserted into the lumen and passed along its length up to the terminus of the
horn. The bevel of the needle was pressed against the anterior wall of the cavity as the
needle was slowly withdrawn from the horn, scraping the entire length of the lumen.
The needle was once again inserted and withdrawn, and this procedure was repeated for
a total of ten passes. The needle was then rotated ninety degrees along its short axis,
such that its bevel faced the medial wall of the uterine horn cavity. Ten passes were
completed once again in this orientation. This was repeated for the posterior and lateral
walls of the uterine horn cavity as well. An identical procedure was performed on the
opposite horn. The mouse was then closed in the fashion previously described and
transferred to a recovery chamber.

Determination of CXCL12 Levels in Blood and Serum
Mice underwent severe Asherman’s Syndrome induction and were divided into
four groups: blood draw and uterine collection twelve hours after induction surgery
(n=3), blood draw and uterine collection twenty-four hours after induction surgery
(n=3), blood draw and uterine collection forty-eight hours after induction surgery
(n=3), and blood draw and uterine collection seventy-two hours after induction surgery
(n=3). A control group was established for each timepoint by performing the sham
surgery previously described (n=3 per time point).

17

Blood Collection
Blood was collected through retro orbital apheresis and cardiac puncture. The
end of a 100µL curette was pressed firmly against the mouse’s orbit and twisted against
its inferior margin to collect blood from the venous sinus. Blood was transferred from
the curette to a 1.5mL Eppendorf tube. This procedure was then repeated on the
opposite side. Next, a twenty-seven gauge needle was inserted through the ventral chest
wall to puncture the heart. Blood was aspirated from the cardiac chambers and added to
the Eppendorf tube containing the previously collected blood. The sample was then
centrifuged at 12,000 relative centrifugal force for 30 minutes. The resultant
supernatant was collected and stored in Eppendorf tubes at -80°C.

Uterine Collection and Processing
Immediately after blood collection, mice were euthanized via carbon dioxide
inhalation with cervical dislocation and uterine samples were collected. The abdominal
wall and peritoneum were incised vertically, and uterine horns identified. Peritoneal fat
was stripped from the uterine horns and discarded. The horns were collected by making
an incision proximal to their connection with ovary and at the junction of the horn and
corpus. The horns were snap frozen using liquid nitrogen and stored in Eppendorf tubes
at -80°C.
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Protein was extracted from the tissue samples using a standardized protocol.
The horns were weighed using an analytical scale and minced using a #21 scalpel
blade. The minced samples were then transferred to a round bottom tube containing a
mixture of non-denaturing lysis buffer, proteinase inhibitor cocktail (Sigma-Aldrich),
and phenylmethylsulfonyl fluoride. The samples were then homogenized for 15
seconds three times. Samples were allowed to cool on ice for 15 seconds in between
homogenization events. The samples were then aliquoted into Eppendorf tubes and
sonicated for 10 seconds three times. The samples were allowed to cool on ice for 15
seconds in between sonication events. The tubes were centrifuged at 12,000 relative
centrifugal force for 30 minutes. The resultant supernatant was collected and used for
further analysis.

Measurement of CXCL12 levels
CXCL12 levels in the serum and uterine horns were determined using a
Quantikine ELISA kit (R&D Systems). The kit protocol was followed without
deviations. Optical densities were measured at 450nm on an iMark microplate reader
(BIO RAD).
The Quantikine ELISA kit was validated on homogenized tissue by performing
standardized curves with the kit-provided calibrator diluent and the previously
described non-denaturing lysis buffer mixture. The curves were analyzed and found to
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be identical. This indicated that the reagents used to extract protein from the samples
did not interfere with the ELISA kit’s reagents, and the resulting optical densities were
reliable. The calibrator diluent was replaced with the lysis buffer mixture, otherwise the
kit protocol was followed without deviations. Optical densities were measured at
450nm on an iMark microplate reader (BIO RAD).

Statistical Analysis
Student’s t-test and Kaplan-Meier survival curve were used for statistical
analysis, and a p value of ≤ 0.05 was considered significant. Comparisons were made
between treatment mice and controls. All error bars represent standard error of the
mean.

Results

Mild Asherman’s Syndrome Fertility Outcomes
Administration of AMD3100 three days after surgery was associated with a
significant decrease in time to pregnancy by 7 estrus cycles compared to normal saline
injection: 15.0 days (SEM=1.4) vs. 20.7 (SEM=2.0) days, (p=0.03) (Figure 1).
Administration of AMD3100 at time of surgery and eight hours before surgery were
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both associated with a nonsignificant decrease in time to pregnancy compared to
normal saline injection: 17.8 days and 18 days, respectively (Figure 1). The likelihood
of pregnancy by 7 estrus cycles was higher in the 3 days post-surgery group compared
to the control group (p=0.004) (Figure 2). All 21 treatment mice delivered by 13 estrus
cycles. 1 of the 7 control mice never gave birth despite reaching a maximal weight of
31 grams.
There was no significant difference in average litter size between the groups:
7.5 (± 1.9) pups in the control group, 7.4 (± 1.9) pups in the eight hours pre surgery
group, 7.0 (± 1.4) pups in the time of surgery group, and 7.7 (± 1.8) pups in the three
days post surgery group (Figure 3). There was no significant difference in percentage of
live pups at birth between the groups: 76 (± 30) % in the control group, 83 (± 35) % in
the eight hours pre surgery group, 83 (± 18) % in the time of surgery group, and 86 (±
22) % in the three days post surgery group (Figure 4).

Asherman’s Induction Technique Comparison
Mice underwent Asherman’s Syndrome induction via one of four techniques:
use of a twenty-seven gauge needle (n=4), a twenty gauge needle (n=5), a twenty-seven
gauge needle and micro scissor incision (n=5), or a twenty gauge needle and micro
scissor incision (n=5). A control group underwent sham surgery with no direct uterine
trauma (n=4).
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The 20G with incision group experienced significantly longer time to delivery
compared to the control group, 46.5±13.7 days vs. 28.0±5.6 days (p=0.045) (Figure 5).
Time to delivery for the 27G needle group, 20G needle group, and 27G needle with
incision group were 25.8±4.0, 35.8±17.0, and 27.2±8.6, respectively (Figure 5). One
mouse in both the 20G needle and 20G needle with incision groups never delivered.
The incision groups both had significantly lower litter sizes than the control
group with 5.8±1.3 pups (p=0.011) for the 27G needle with incision group and 3.5±0.5
pups (p=0.0007) for the 20G needle with incision group (Figure 6). The litter sizes for
the 27G needle group, 20G needle group, and control group were 7.3±2.2, 7.8±2.3, and
8.5±0.5 pups respectively (Figure 6). The 20G needle with incision group had a live
birth fraction (number of live pups divided by total litter size) of 0. The live birth
fraction of the 27G needle group, 20G needle group, 27G needle with incision group,
and control group were 0.32±0.41, 0.80±0.23, 0.53±0.41, and 0.93±0.11, respectively
(Figure 6). Two mice in both the 20G needle and 27G needle with incision groups
experienced miscarriages. The 20G needle group experienced 0.4±0.5 miscarriages per
mouse. The 20G needle with incision group experienced 0.6±0.8 miscarriages per
mouse (Figure 6).
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Serum CXCL12 Concentrations
Serum CXCL12 concentrations were determined using ELISA at four different
time points after surgery: twelve hours post surgery, twenty-four hours post surgery,
forty-eight hours post surgery, and seventy-two hours post surgery (n=3/time point).
The serum CXCL12 concentrations for the sham surgery were 6.72 (± 5.05) ng/mL
twelve hours post surgery, 6.88 (± 1.66 ) ng/mL twenty-four hours post surgery, 10.34
(± 2.72) ng/mL forty-eight hours post surgery, and 9.07 (± 1.29) ng/mL seventy-hours
post surgery (Firgure 7). The serum CXCL12 concentrations for the treatment surgery
were 6.26 (± 2.99) ng/mL twelve hours post surgery, 8.97 (± 1.01) ng/mL twenty-four
hours post surgery, 7.39 (± 1.46) ng/mL forty-eight hours post surgery, and 6.43 (±
0.18) ng/mL seventy-two hours post surgery (Firgure 7). There were no signifcant
differences in serum CXCL12 levels between AS induction mice compared to controls
mice.

Uterine CXCL12 Concentrations
Tissue CXCL12 concentrations in the uterus were determined using ELISA at
four different time points after surgery: twelve hours post surgery, twenty-four hours
post surgery, forty-eight hours post surgery, and seventy-two hours post surgery. The
uterine CXCL12 concentrations for the sham surgery were 0.20 (± 0.12) ng/mL twelve
hours post surgery, 0.36 (± 0.17 ) ng/mL twenty-four hours post surgery, 0.27 (± 0.09)
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ng/mL forty-eight hours post surgery, and 0.36 (± 0.03) ng/mL seventy-two hours post
surgery (Firgure 8). The uterine CXCL12 concentrations for the treatment surgery were
0.23 (± 0.08) ng/mL twelve hours post surgery, 0.36 (± 0.08) ng/mL twenty-four hours
post surgery, 0.58 (± 0.10) ng/mL forty-eight hours post surgery, and 0.16 (± 0.12)
ng/mL seventy-two hours post surgery (Figure 8). Uterine CXCL12 concentrations
were significantly increased in the treatment group forty-eight hours post surgery
compared to the control group (p=0.03) (Figure 8).
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Time to Pregnancy by 7 estrus cycles
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Figure 1: AMD3100 Trial- Time to Pregnancy Bar Chart: Mice underwent mild AS induction
surgery and given a 10mg/kg subcutaneous AMD3100 injection eight hours before surgery
(n=7), at time of surgery (n=7), or three days post-surgery (n=7). The control group
underwent AS induction and received a subcutaneous normal saline injection at time of

surgery (n=7). Mice were subsequently mated and followed for time to pregnancy for seven
estrus cycles. The three-day postoperative injection group had a significantly lower time to
pregnancy compared to the control group: 15.0 days vs. 20.7 days, *p=0.03.

Pregnancy Achieved by 7 Estrus Cycles

Control

Percent Survival

100

8 Hours Pre Surgery
Time of Surgery
3 Days Post Surgery

50

0
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10

20

30

Days Elapsed
Figure 2: AMD3100 Trial- Time to Pregnancy Kaplan–Meier Curve: Fertility data from the
AMD3100 trial is represented here as a Kaplan-Meier Curve. The three-day postoperative
group achieved pregnancy significantly sooner than the control group (p=0.004).
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Figure 3: AMD3100 Trial- Litter Size: Litter size was recorded for all four groups. While litter
sizes varied among the groups (range from 4 to 10 pups), there was no significant difference

in litter size between the groups.
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0
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Figure 4: AMD3100 Trial- Live Births: The number of live pups was recorded for all four

groups. The percentage of pups that were alive immediately postpartum is shown for each
group. There was no significant difference in percentage of live pups between the groups.

26

Time to Delivery
60

Control
20G
27G

Days

40

20G,I
27G,I

20

0

20G

27G

20G,I

27G,I Control

Technique
Figure 5: Technique Comparison- Delivery Time: Mice underwent Asherman’s Syndrome

induction via one of four techniques: 20G needle (n=4), 27G needle (n=5), 20G needle with
incision (n=5), or 27G needle with incision (n=5). Control mice underwent sham surgery
without uterine trauma. The 20G needle with incision group experienced significantly

increased time to delivery
compared to the
control group: 46.5±13.7 vs. 28.0±5.6 days
Pregnancy
Outcomes
(*p=0.045).
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Litter Size
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Figure 6: Technique Comparison- Pregnancy Outcomes: Mean litter size and miscarriages

were recorded for each group. The 20G needle with incision and 27G needle with incision
groups had significantly smaller litter sizes compared to the control group: 3.5±0.5 pups

(p=0.0007) and 5.8±1.3 pups (p=0.011), respectively. Only the 20G needle and 20G needle

with incision groups experienced miscarriages. The 20G needle with incision group had the
smallest mean litter size and most miscarriages.

CXCL12 (ng/mL)

27

C= Control
T= Treatment

Figure 7: Serum Concentration CXCL12: Relative serum concentrations of CXCL12 for four

different time points after severe Asherman’s Syndrome induction or sham surgery. There was

no significant difference in serum CXCL12 levels between treatment and control mice. n=3
for each time point.

C= Control

CXCL12 (ng/mL)

T= Treatment

Figure 8: Relative Uterine CXCL12 Concentration: Relative uterine concentrations of
CXCL12 for four different time points after severe Asherman’s Syndrome induction or sham

surgery. A statistically significant peak of 0.58 ng/mL occurred at 48 hours in the severe AS
mice compared to the sham group (*p=0.03)
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Discussion

I set out to observe the effects of AMD3100 administration on fertility outcomes
in a murine model of AS. Subsequently, I developed a technique for induction of a
more severe AS phenotype that better recapitulates what occurs in women struggling
with infertility resulting from AS. Furthermore, I determined for the first time the
levels of CXCL12 in serum and uteri following injury, which allowed for the
determination of the optimal timing for AMD3100 administration to help restore
normally functioning endometrium following induction of AS.

Mild Asherman’s Syndrome Fertility Outcomes
The trial in the mild AS model showed that AMD3100 injection three days post
induction surgery yielded the fastest resumption of fertility. This suggests that stem
cells were best mobilized and able to enact their regenerative effects on the uterus at
this timepoint. This may be due to the timing of inflammation within the uterine tissue.
Injury caused by trauma releases reactive cytokines which facilitate tissue healing as
well as recruitment of immune cells. One cytokine of particular importance is
CXCL12/SDF-1 which has been shown to attract bone marrow derived stem cells23.
There was no significant difference in litter size or percentage of live pups in the
litter between the four groups. This suggests that the effects of stem cell mobilization
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between the different time points, while having a significant effect on the rate of
regeneration of the uterus, did not have an observable effect on its ability to ultimately
provide a suitable environment for implantation and development of murine pups. This
may indicate that the mild model did not induce trauma severe enough to manifest
changes in these outcomes. It must be noted that the cohort size, n=28, may not be
large enough to detect differences in these parameters.
Although litter size was recorded, no data was recorded on pup birth weight. It
is possible that scar tissue formation would affect nutrient delivery in utero, and
ultimately pup health and weight. A subsequent experiment could be performed where
pups are weighed at or near time of birth, and their average mass compared between
mice receiving AMD3100 after AS induction and mice receiving normal saline.
After 7 estrus cycles, all but one mouse became pregnant. As such, it was felt
that the mild AS model was not the best method to recapitulate AS in humans.
Therefore, I decided to conduct additional experiments aimed at finding a severity of
AS induction that better represented the condition in humans.

Optimization of a Murine Model of Asherman’s Syndrome

30
Four different techniques were tested for inducing Asherman’s Syndrome in
mice. Micro scissor incision at the junction of the uterine horn and uterine corpus
resulted in significantly smaller litter sizes as previously described23. Use of a larger,
20G needle resulted in miscarriages, where use of a 27G needle did not, suggesting
severity of injury is correlated with the diameter of the needle. The 20G with incision
technique led to the lowest litter size, no live births, most miscarriages, and longest
time to delivery. This disease state most closely mimics patients affected by severe
Asherman’s Syndrome, the population most in need of new treatment modalities.
The severe Asherman’s Syndrome technique described above has the benefit of
uniformly traumatizing the lumen of the uterine horns by means that can be easily
replicated. This model may be used to further study Asherman’s Syndrome, local
uterine inflammation, and the effects of stem cell mobilization with AMD3100. Our
trial of AMD3100 use in mild AS showed post operative AMD3100 injection to be
superior to pre operative or time of surgery administration, however, as I continued to
follow mice pregnancies after 7 estrus cycles, I noted that most mice became pregnant.
As such I developed a more severe AS model and aimed to determine the ideal
timepoint for AMD 3100 administration in this model by utilizing CXCL12
measurements as a maker for peak stem cell mobilization.
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CXCL12 Concentrations
There was no significant difference in serum CXCL12 concentrations between
the different time points. CXCL12 concentrations while physiologically consequential
in areas of local inflammation, may not cause drastic variations in cell function in the
systemic circulation. BMDSC’s follow a gradient of CXCL12 chemotactically to reach
target organs28. Perhaps it is the differential in chemokine concentration at the injury
site compared to the circulation that leads to homing and engraftment of regenerative
cell types. If this was the case, the average serum concentration of such chemokines
would be inconsequential, and instead the concentration at the capillary and tissue level
that drives wound healing via stem cell engraftment. To explore this idea, I measured
CXCL12 concentrations within uterine samples of severe Asherman’s Syndrome model
mice post operatively.
There was a statistically significant peak in uterine CXCL12 concentrations in
severe AS model mice forty-eight hours post surgery. This peak was significantly
higher than the concentration measured in sham mice. This supports the idea that direct
trauma to tissues, for example the uterus, facilitates the transcription of chemokines like
CXCL12, which play an invaluable role in stem cell recruitment. The difference in
uterine CXCL12 concentrations between sham and AS induction surgery gives further
insight into past observations that local inflammation increases stem cell engraftment to
the uterus13.
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The data also shows a clear pattern of increasing uterine CXCL12
concentrations in the first forty-eight hours after surgery before falling off abruptly at
seventy-two hours. This suggests there is an optimal window for stem cell mobilization
with AMD3100. It is still unclear if the true peak lies at forty-eight hours, between
twenty-four and forty-eight hours, or between forty-eight and seventy-two hours.
Further experiments will be needed, ideally with a larger cohort, to elucidate a more
precise timing of peak CXCL12 concentration in the healing uterus.
Forty-eight hours after surgery may represents a state of peak inflammation in
the healing uterus. Theoretically this translates to maximum intensity in stem cell
recruitment as BMDSC’s passing through the capillaries perfusing the endometrium are
drawn to leave the circulation and enter the injured tissues. Once in the endometrium,
these cells can assist with tissue regeneration by releasing trophic factors and recruiting
additional immune cells29.
Mouse uterine samples were diluted using a lysis buffer solution and no effort
was made to compare the measured CXCL12 concentration to the original dry protein
weights of the samples. Thus, it should be noted that the concentrations measured in the
uterus in the above experiment can only communicate relative peaks in CXCL12 values
rather than the absolute tissue concentrations after surgery.

Timing of AMD3100 Injection
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The fertility outcomes suggest that post surgical injection of AMD3100 is
superior to administration at time of surgery or in the preoperative period. As indicated
by tissue CXCL12 concentrations, the uterus is in a particularly inflammatory state and
signaling for stem cell recruitment is at its peak forty-eight hours post surgery. To
ensure maximal availability of BMDSC’s in the peripheral circulation to act upon this
signal, an appropriate dose of AMD3100 would need to be administered six to nine
hours before this target inflammatory state. This translates to an ideal administration
time of thirty-nine to forty-two hours after surgical intervention to facilitate maximal
healing and restoration of reproductive function. Given that peak uterine CXCL12
concentrations could lie several hours before or after the forty-eight hour peak observed
in the above experiment, a goal of AMD3100 administration between thirty-three and
forty-eight hours after surgery would be reasonable.

Special Considerations of Research During the COVID-19 Pandemic
The COVID-19 pandemic has caused disruptions in virtually all global sectors
including telecommunications, information technology, finance, and healthcare.
Scientific research was not unaffected by this historic world event.
Conducting scientific research during a pandemic creates its own list of unique
consequences and inconveniences. For instance, the typical channels for the exchange
of information and ideas were not operating in their usual fashion. Laboratory meetings
were temporarily canceled before being moved to an entirely virtual platform. This has
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the effect of stifling communication between laboratory team members, an essential
component of scientific discussion and inquiry.
The pandemic also had the effect of delaying the acquisition of certain essential
research supplies. This caused deviations in the planned timeline of experimentation
and created further difficulty in coordinating joint tasks between research members.
While certain reagents and equipment are kept in excess within the lab space, others
have a definitive shelf life making timely access to additional quantities essential to
their successful use.
Overall, the pandemic created an air of uncertainty and tumultuousness which
complicated the research process. Ultimately, through the consistent support of research
mentors and colleagues, I was able to complete this project despite these challenges and
without compromising the scientific quality or academic integrity of my work.

Future Directions and Next Steps
Asherman’s Syndrome is a rare disease state characterized by intrauterine
synechiae which can cause life changing reproductive consequences, most notably
infertility. Standard of care treatments for Asherman’s Syndrome result in high
recurrence rates and low probabilities of successful pregnancy. Stem cell technologies
are a promising avenue for augmenting current treatment methods. AMD3100, in
particular, has the unique quality of offering measurable improvements in fertility
outcomes with a single-dose injection.
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Stem cell mobilization can ideally be used in conjunction with surgical
treatment of AS to prevent recurrence of intrauterine adhesions and facilitate restoration
of normal endometrial function. This would reduce the need for repeat hysteroscopies,
a common occurrence in this disease state, and increase the probability of successful
implantation for individuals seeking future pregnancy. A trial of AMD3100 in human
subjects is an essential next step is exploring this therapeutic option. Overall, this data
is promising and may represent a novel treatment option in women suffering from
infertility due to Asherman’s Syndrome.
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